A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

A Phase 1, Randomized, Placebo-controlled, Single-dose Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

This is a Phase 1 study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI7814 in healthy adult subjects.

This is a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI7814 in healthy adult male subjects and female subjects of non-childbearing potential.

Inclusion Criteria:

• Aged 18 years up to and including 49 years at the time of first dose of investigational product
• Healthy by medical history, physical examination, and laboratory studies
• Body weight 50-125 kilogram (kg); body mass index 19.0-32.0 kilogram per square meter (kg/m^2) (inclusive)
• Females must be of non-childbearing potential.

Exclusion criteria:

• Any acute illness within 30 days of screening
• Concurrent enrollment in another clinical trial
• The subject has a positive drug/alcohol screen at screening or Day -1
• Pregnancy
• Current cigarette smokers
• History of cancer other than non-melanoma skin cancer or in situ carcinoma of the cervix treated with apparent success
• Use of immunosuppressive medications
• Subjects who have an unresolved infection with any Neisseria species
• Subjects who have had their spleen removed for any reason.